<code id='BC71920548'></code><style id='BC71920548'></style>
    • <acronym id='BC71920548'></acronym>
      <center id='BC71920548'><center id='BC71920548'><tfoot id='BC71920548'></tfoot></center><abbr id='BC71920548'><dir id='BC71920548'><tfoot id='BC71920548'></tfoot><noframes id='BC71920548'>

    • <optgroup id='BC71920548'><strike id='BC71920548'><sup id='BC71920548'></sup></strike><code id='BC71920548'></code></optgroup>
        1. <b id='BC71920548'><label id='BC71920548'><select id='BC71920548'><dt id='BC71920548'><span id='BC71920548'></span></dt></select></label></b><u id='BC71920548'></u>
          <i id='BC71920548'><strike id='BC71920548'><tt id='BC71920548'><pre id='BC71920548'></pre></tt></strike></i>

          
          WSS

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion